BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving aromatase inhibitors (AIs). The objective of this study was to evaluate the perceived onset, characteristics, and risk factors for AI-related arthralgia (AIA). METHODS: In a cross-sectional survey of postmenopausal BCS who were receiving adjuvant AI therapy at a university-based oncology clinic, patient-reported attribution of AIs as a cause of joint pain was used as the primary outcome. Multivariate logistic regression analyses were performed to evaluate risk factors. RESULTS: Among 300 survey respondents, 139 (47%) attributed AI as a cause of their current arthralgia. Of those patients, 74% recognized the onset of AIA within 3 months of starting medication, and 67% rated joint pain as moderate or severe in the previous 7 days. In multivariate logistic regression analyses, the time since last menstrual period (LMP) was the only significant predictor of AIA. Controlling for covariates, the women who had their LMP within 5 years had the highest probability of reporting AIA (73%), whereas those who had their LMP > or =10 years previously had the lowest probability of reporting AIA (35%; adjusted odds radio, 3.39; 95% confidence interval, 1.21-9.44; P = .02). Wrists/hands, ankles/feet, elbows, and knees appeared to be associated more strongly with AI-related symptoms than non-AI-related joint symptoms (all P < .01). CONCLUSIONS: AIA was common, began within the first 3 months of therapy in most patients, and appeared to be related inversely to the length of time since cessation of menstrual function. These findings suggest that estrogen withdrawal may play a role in the mechanism of this disorder.
BACKGROUND:Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving aromatase inhibitors (AIs). The objective of this study was to evaluate the perceived onset, characteristics, and risk factors for AI-related arthralgia (AIA). METHODS: In a cross-sectional survey of postmenopausal BCS who were receiving adjuvant AI therapy at a university-based oncology clinic, patient-reported attribution of AIs as a cause of joint pain was used as the primary outcome. Multivariate logistic regression analyses were performed to evaluate risk factors. RESULTS: Among 300 survey respondents, 139 (47%) attributed AI as a cause of their current arthralgia. Of those patients, 74% recognized the onset of AIA within 3 months of starting medication, and 67% rated joint pain as moderate or severe in the previous 7 days. In multivariate logistic regression analyses, the time since last menstrual period (LMP) was the only significant predictor of AIA. Controlling for covariates, the women who had their LMP within 5 years had the highest probability of reporting AIA (73%), whereas those who had their LMP > or =10 years previously had the lowest probability of reporting AIA (35%; adjusted odds radio, 3.39; 95% confidence interval, 1.21-9.44; P = .02). Wrists/hands, ankles/feet, elbows, and knees appeared to be associated more strongly with AI-related symptoms than non-AI-related joint symptoms (all P < .01). CONCLUSIONS: AIA was common, began within the first 3 months of therapy in most patients, and appeared to be related inversely to the length of time since cessation of menstrual function. These findings suggest that estrogen withdrawal may play a role in the mechanism of this disorder.
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: James J Mao; Deborah W Bruner; Carrie Stricker; John T Farrar; Sharon X Xie; Marjorie A Bowman; Donna Pucci; Xiaoyan Han; Angela DeMichele Journal: Integr Cancer Ther Date: 2009-06 Impact factor: 3.279
Authors: Katherine D Crew; Jillian L Capodice; Heather Greenlee; Arlyn Apollo; Judith S Jacobson; George Raptis; Kimberly Blozie; Alex Sierra; Dawn L Hershman Journal: J Cancer Surviv Date: 2007-10-12 Impact factor: 4.442
Authors: Victoria K Shanmugam; James McCloskey; Beth Elston; Sandra J Allison; Jennifer Eng-Wong Journal: Breast Cancer Res Treat Date: 2011-11-11 Impact factor: 4.872
Authors: Kirsten A Nyrop; Leigh F Callahan; Christine Rini; Mary Altpeter; Betsy Hackney; Amy DePue; Anne Wilson; Arielle Schechter; Hyman B Muss Journal: Support Care Cancer Date: 2016-01-12 Impact factor: 3.603
Authors: Brian Leyland-Jones; Kathryn P Gray; Mark Abramovitz; Mark Bouzyk; Brandon Young; Bradley Long; Roswitha Kammler; Patrizia Dell'Orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Vernon J Harvey; Patrick Neven; Isabelle Treilleux; Birgitte Bruun Rasmussen; Rudolf Maibach; Karen N Price; Alan S Coates; Aron Goldhirsch; Olivia Pagani; Giuseppe Viale; James M Rae; Meredith M Regan Journal: Breast Cancer Res Treat Date: 2015-05-03 Impact factor: 4.872
Authors: Jun J Mao; Annie Chung; Adrian Benton; Shawndra Hill; Lyle Ungar; Charles E Leonard; Sean Hennessy; John H Holmes Journal: Pharmacoepidemiol Drug Saf Date: 2013-01-16 Impact factor: 2.890
Authors: Jun J Mao; Sharon X Xie; John T Farrar; Carrie T Stricker; Marjorie A Bowman; Deborah Bruner; Angela DeMichele Journal: Eur J Cancer Date: 2013-10-24 Impact factor: 9.162
Authors: Kelley M Kidwell; Steven E Harte; Daniel F Hayes; Anna Maria Storniolo; Janet Carpenter; David A Flockhart; Vered Stearns; Daniel J Clauw; David A Williams; N Lynn Henry Journal: Cancer Date: 2014-05-06 Impact factor: 6.860